Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824426 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL744334 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL21367565 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL17702826 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL3698323 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL11006613 | 1.00 | MEN1 (0.37) | MEN1KMT2AFUCA1GBA1GAA | |
| SCHEMBL27338815 | 0.80 | — | — | |
| SCHEMBL19003146 | 0.76 | MEN1 (0.39) | MEN1KMT2AGBA1GAA | |
| SCHEMBL17178262 | 0.76 | MEN1 (0.39) | MEN1KMT2AGBA1GAA | |
| SCHEMBL12017370 | 0.76 | MEN1 (0.39) | MEN1KMT2AGBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1659 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107335-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASES BY INHIBITING EFHD1 | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | XALUD THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| EP-4642787-A2 | MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS | SUNVAX MRNA THERAPEUTICS (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250228262-A1 | LOW SUGAR, HIGH FIBER CHEWABLE SWEETS | TATE & LYLE SOLUTIONS USA LLC (US) | 2025-07-17 | — | — | US | claimed |
| US-20250213698-A1 | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | claimed |
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ARCTURUS THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | claimed |
| US-12287339-B2 | Analysis method, microorganism identification method, and testing method | SHIMADZU CORPORATION (JP) | 2025-04-29 | — | — | US | claimed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| EP-4525855-A1 | INTERCALATING SUGAR MOLECULES | Xalud Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-1335687-A2 | METHOD FOR RESTORING A DAMAGED OR DEGENERATED INTERVERTEBRAL DISC | Bio Syntech Canada Inc. (CA) | 2003-08-20 | — | — | EP | claimed |
| EP-1333869-A2 | FILLER COMPOSITION FOR SOFT TISSUE AUGMENTATION | Bio Syntech Canada Inc. (CA) | 2003-08-13 | — | — | EP | claimed |
| EP-1003567-B1 | TEMPERATURE-CONTROLLED pH-DEPENDANT FORMATION OF IONIC POLYSACCHARIDE GELS | BIOSYNTECH CANADA INC (CA) | 2003-08-06 | — | — | EP | claimed |
| EP-1229940-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA INC. (CA) | 2002-08-14 | — | — | EP | claimed |
| WO-2002040072-A2 | FILLER COMPOSITION FOR SOFT TISSUE AUGMENTATION AND RECONSTRUCTIVE SURGERY | BIO SYNTECH CANADA INC. (CA) | 2002-05-23 | — | — | WO | claimed |
| WO-2002040070-A2 | METHOD FOR RESTORING A DAMAGED OR DEGENERATED INTERVERTEBRAL DISC | BIO SYNTECH CANADA INC. (CA) | 2002-05-23 | — | — | WO | claimed |
| US-6344488-B1 | Temperature-controlled pH-dependent formation of ionic polysaccharide gels | BIO SYNTECH | 2002-02-05 | — | — | US | claimed |
| WO-2001036000-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA, INC. (CA) | 2001-05-25 | — | — | WO | claimed |
| EP-1003567-A1 | TEMPERATURE-CONTROLLED pH-DEPENDANT FORMATION OF IONIC POLYSACCHARIDE GELS | Bio-Syntech Ltd. (CA) | 2000-05-31 | — | — | EP | claimed |
| WO-1999007416-A1 | TEMPERATURE-CONTROLLED pH-DEPENDANT FORMATION OF IONIC POLYSACCHARIDE GELS | BIO-SYNTECH LTD. (CA) | 1999-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ASGR1, FCGR2A, FCGR3B | MEN1 4241/4885KMT2A 4273/4885FUCA1 67/4885 |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | MEN1 1491/4885KMT2A 1796/4885FUCA1 1347/4885 |
| US-20250213698-A1 | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | PAICS, ABCG2, FOLR1 | MEN1 3025/4885KMT2A 4117/4885FUCA1 2876/4885 |
| US-20260137806-A1 | INTERCALATING SUGAR MOLECULES | SLC2A1, SLC2A2, SLC2A4 | MEN1 1689/4885KMT2A 3581/4885FUCA1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.